Profile: Agilent Technologies Inc (A)
28 Apr 2017
Agilent Technologies, Inc., incorporated on May 4, 1999, provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. The Company has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. The life sciences and applied markets business segment brings together the Company's analytical laboratory instrumentation and informatics. The Company's diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. The Company's Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.
Life Sciences and Applied Markets Business segment
The Company's life sciences and applied markets business segment provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its product categories include liquid chromatography (LC) systems and components; liquid chromatography mass spectrometry (LCMS) systems; gas chromatography (GC) systems and components; gas chromatography mass spectrometry (GCMS) systems; inductively coupled plasma mass spectrometry (ICP-MS) instruments; atomic absorption (AA) instruments; microwave plasma-atomic emission spectrometry (MP-AES) instruments; inductively coupled plasma optical emission spectrometry (ICP-OES) instruments; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing, and vacuum pumps and measurement technologies.
Diagnostics and Genomics Business segment
The Company's diagnostics and genomics business segment consists of approximately three areas of activity providing solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. Its pathology solutions business is focused on product offerings to cancer diagnostics and anatomic pathology workflows. The portfolio of offerings includes immunohistochemistry (IHC), In Situ Hybridization (ISH), Hematoxylin and Eosin (H&E), staining and special staining. Its genomics business includes arrays for deoxyribonucleic acid (DNA) mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as Next Generation Sequencing (NGS) target enrichment. Its nucleic acid solutions business provides equipment and capability focused on production of synthesized oligonucleotides under pharmaceutical Good Manufacturing Practices (GMP) conditions for use as active pharmaceutical ingredients (API) in a class of drugs that utilize nucleic acid molecules for disease therapy.
Agilent CrossLab Business segment
The Agilent CrossLab business segment's majority of the portfolio is vendor neutral, which means the Company can serve and supply customers regardless of their instrument purchase choices. Its solutions range from chemistries and supplies to services and software helping to connect the entire lab. Its product categories in consumables include GC and LC columns, sample preparation products, custom chemistries and a selection of laboratory instrument supplies. Its services include startup, operational, training and compliance support, as well as asset management and consultative services that rise customer productivity.
Agilent Technologies Inc
5301 Stevens Creek Blvd
SANTA CLARA CA 95051-7201
Company Web Links
- BRIEF-Agilent Technologies introduces a new target enrichment solution for next-generation DNA sequencing
- BRIEF-Agilent Technologies announces board changes
- BRIEF-Agilent Technologies reports Q1 GAAP EPS $0.52
- BRIEF-Agilent Technologies' CEO Michael Mcmullen 2016 total compensation was $8.9 mln vs. $7.2 mln in 2015 - SEC Filing
- BRIEF-Agilent Technologies increases cash dividend to 13.2 cents per share